Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip
Status:
Completed
Trial end date:
1997-04-01
Target enrollment:
Participant gender:
Summary
We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical
trial in patients with hip osteoarthritis in order to:
- evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive
decrease in joint space width observed in patients with hip osteoarthritis
- to investigate the potential structure-modifying effect of diacerein in patients with
hip osteoarthritis
This study compare also after ten years the percentage of patients in each treatment group
who require a hip replacement surgery